Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits 'Too Long'

As Amarin expects jump in Vascepa sales from potential label expansion allowing larger patient group, John Thero notes competitors fail to show broader cardiovascular risk reduction, but consumers still hear omega-3 supplements "might work."

The head of the pharma firm marketing a drug containing a synthetically produced omega-3 and indicated to treat severely high triglycerides says time's up for fish oil dietary supplements' claims of heart health benefits.

"People have been hearing for too long that dietary supplements might work," said John Thero, Amarin Corp. PLC president...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation